The fair value of the Company's available-for-sale investments as of and were million and million, respectively. The decrease was caused by the sale of million of the Company’s investment in ChemoCentryx, Inc. (CCXI) in the quarter of fiscal and the maturity of million in corporate bond securities held by Advanced Cell Diagnostics (ACD). This decrease was partially offset by year-over-year increases in the stock price of CCXI, from per share at to per share at resulting in a million increase in the fair value of the Company's investment in CCXI. The amortized cost basis of the Company's investment in CCXI as of and was million and million, respectively.

 

The unrealized gain (loss) on available-for-sale investments for fiscal includes a million unrealized gain related to our investment in CCXI. As of the stock price of CCXI was per share compared to our cost basis of per share.

 

Inventories consist of (in thousands):

 

		June 30,
		201 8				201 7
Raw materials		$	30,956			$	22,074
Finished goods			54,692				38,077
Inventories, net		$	85,648			$	60,151

 

 

Property and equipment consist of (in thousands):

 

		June 30,
		2018				2017
Cost:
Land		$	7,065			$	6,270
Buildings and improvements			170,110				158,495
Machinery, equipment and other			107,625				98,596
Property and equipment			284,800				263,361
Accumulated depreciation and amortization			(139,452	)			(128,237	)
Property and equipment, net		$	145,348			$	135,124

Intangibles assets were comprised of the following (in thousands):

 

							June 30,
		Useful Life (years)					2018				201 7
Developed technology		9	-	15			$	305,303			$	276,959
Trade names		2	-	20				89,608				87,092
Customer relationships		7	-	16				212,228				204,243
Non-compete agreements		3	-	5				-				3,264
Patents			10					1,401				633
Intangible assets								608,540				572,191
Accumulated amortization								(162,208	)			(120,149	)
Intangibles assets, net							$	446,332			$	452,042

 

Changes to the carrying amount of net intangible assets consist of (in thousands):

 

		June 30,
		2018				2017
Beginning balance		$	452,042			$	310,524
Acquisitions			40,673				185,869
Other additions			908				976
Amortization expense			(47,076	)			(44,393	)
Currency translation			(215	)			(934	)
Ending balance		$	446,332			$	452,042

Amortization expense related to technologies included in cost of sales was million million, and million in fiscal and respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was million, million, and million, in fiscal and respectively.

 

The estimated future amortization expense for intangible assets as of is as follows (in thousands):

 

2019		$	47,841
2020			47,137
2021			46,772
2022			45,060
2023			43,176
Thereafter			216,346
Total		$	446,332

Changes in goodwill by reportable segment and in total consist of (in thousands):

 

		Biotechnology				Protein Platforms				Diagnostics				Total
June 30, 2016		$	108,723			$	218,889			$	103,270			$	430,882
Acquisitions (Note 2)			147,484				-				-				147,484
Prior year acquisitions			-				1,809				-				1,809
Currency translation			(1,277	)			128				-				(1,149	)
June 30, 2017		$	254,930			$	220,826			$	103,270			$	579,026
Acquisitions (Note 2)			16,186				-				2,910				19,096
Currency translation			759				(815	)			(176	)			(232	)
June 30, 2018		$	271,875			$	220,011			$	106,004			$	597,890

Other assets consist of (in thousands):

 

		June 30,
		2018				2017
Investments		$	2,606			$	40,385
Other			2,660				3,617
Other long-term assets		$	5,266			$	44,002

As of the Company had million of other assets compared to million as of The decrease was due to the impairment and sale of its investment in Astute Medical, Inc. (Astute) during fiscal   The Company held a ownership interest in Astute and accounted for the investment under the cost method. During the quarter of fiscal the Company learned that Astute intended to accept an offer to sell the company to a party. As a result of this triggering event, the Company completed an impairment assessment and determined that a portion of its investment in Astute was other-than-temporarily impaired and adjusted the carrying value of its investment by million to other income (expense) in the accompanying Consolidated Statements of Earnings and Comprehensive Income. During the quarter of fiscal the Company decreased its investment in Astute by another million after receiving cash payment upon the closing of the acquisition. As of the Company has a million remaining investment in Astute for the additional cash payment it expects to receive upon liquidation of the escrow account.

 

 

Supplemental cash flow information was as follows (in thousands):

 

		Year Ended June 30,
		2018				2017				2016
Income taxes paid		$	35,076			$	42,900			$	44,900
Interest paid			9,844				7,452				1,661
Non-cash activities:
Acquisition-related liabilities (1)			1,396				32,856				42,259

 

Consists of holdback payments due at future dates and liabilities for contingent consideration. Further information regarding liabilities for contingent consideration can be found in Note